Business Wire

 GLEIF Confirms J.P. Morgan as First Validation Agent in the Global LEI System

19.11.2020 11:59:00 EET | Business Wire | Press release

Share

The Global Legal Entity Identifier Foundation (GLEIF) today announces that J.P. Morgan has become the first Validation Agent in the Global LEI System.

The Validation Agent Framework, announced by GLEIF in September 2020, enables financial institutions to improve their customer experience, accelerate client lifecycle management and reduce costs by using ‘business-as-usual’ know-your-customer (KYC) and anti-money laundering (AML) onboarding procedures to facilitate LEI issuance for their clients.

J.P. Morgan and LEI issuer, Business Entity Data B.V. (BED), a wholly owned subsidiary of The Depository Trust & Clearing Corporation (DTCC), have together issued the first LEI under the new Validation Agent model, via BED’s GMEI Utility service.

J.P. Morgan’s Managing Director, Reference Data Strategy, George Brandman, comments: “Working as a Validation Agent will allow us to improve our client onboarding experience as well as create valuable industry LEI reference data. If a majority of financial institutions implemented this service, it would greatly multiply the number of LEIs in production to the benefit of all.”

“DTCC is pleased to issue the first LEI via the Validation Agent model for J.P. Morgan, leveraging our GMEI Utility,” adds Matt Stauffer, Managing Director and Head of Institutional Trade Processing at DTCC. “Our collaboration with J.P. Morgan demonstrates the additional efficiencies that can be achieved through broader utilization of LEIs and supports our core mission of bringing increased efficiency and resiliency to the industry.”

Stephan Wolf, CEO, GLEIF, comments: “By becoming Validation Agents, financial institutions realize a range of operational and strategic benefits, both now and in the longer-term. Not only can J.P. Morgan streamline its client onboarding and lifecycle management processes, thereby improving its customer experience, it can also use the LEIs in innovative service offerings.”

As well as delivering a faster, more convenient customer experience, Validation Agents can also capitalize on new opportunities to add client value and achieve market differentiation. By expanding LEI issuance beyond clients that require an LEI for financial compliance, a Validation Agent can equip its whole business client base with globally recognized identities that can be leveraged in new services and across borders with any counterparty or supplier around the world.

“Increasing LEI volumes and broadening their usage will solve the issue of trust in financial transactions globally,” adds Wolf. “Validation Agents like J.P. Morgan will play a key part in making this vision a reality. They contribute to growth across the entire financial ecosystem and ultimately will benefit all stakeholders and the broader global economy.”

For more information on the Validation Agent role, please visit the GLEIF website.

- ENDS -

Full resolution images and logos can be downloaded via this link
https://www.gleif.org/en/newsroom/gleif-graphics-images

Relevant link
https://www.gleif.org/en

Source:
Global Legal Entity Identifier Foundation, St. Alban-Vorstadt 5, 4052 Basel, Switzerland
Chairman of the Board: Steven Joachim, CEO: Stephan Wolf
Commercial-Register-No.: CHE-200.595.965, VAT-No.: CHE-200.595.965MWST
LEI: 506700GE1G29325QX363

: http://bit.ly/1OXTYLo | : http://bit.ly/1Me7uZx | GLEIF Blog: http://bit.ly/1LylXkn

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Elisabeth Dean / Ellie Bokros, iseepr
elisabeth@iseepr.co.uk / ellie@iseepr.co.uk
+44 (0) 113 350 1922

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release

Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl

Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi

Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 09:00:00 EEST | Press release

Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to digital to manage their businesses. In late 2025, Tide received a strategic investment from TPG, a leading global alternative asset manager, valuing the company at $1.5 billion. Oliver Prill, CEO of Tide, said: “We are delighted to be crossing the 2 million member milestone. This number is a testament to the trust that our members place in us in all our markets. Behind every

Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 01:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm

SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 20:00:00 EEST | Press release

SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye